2-(1-丁戊基)吡啶 | 2961-49-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(1-丁戊基)吡啶
• 中文别名: 2-(1-丁基戊基)-吡啶
• 英文名称: 2-(1'-Butyl-pentyl)-pyridin
• 英文别名: 4--pyridin；2--pyridin；2-(1-butyl-pentyl)-pyridine；2-(5-nonyl)pyridine；Pyridine, 2-(1-butylpentyl)-；2-nonan-5-ylpyridine
• CAS: 2961-49-1
• 化学式: C₁₄H₂₃N
• 分子量: 205.343
• InChiKey: YGCMUHWPXXEZCR-UHFFFAOYSA-N

物化性质

• 保留指数：
  1451.8

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(1-丁戊基)吡啶 在 铁粉 sodium amide 作用下， 以 氨 、 水 、 N,N-二甲基苯胺 为溶剂， 以2.7%的产率得到6,6'-di-(5-nonyl)-2,2'-bipyridyl
  参考文献：
  名称：

  Substituted 2,2'-bipyridyl compounds and process for preparing same

  摘要：

  一种制备取代2,2'-联吡啶化合物的方法以及制备的几种化合物，该方法包括以下步骤：首先选择一个符合定义的取代吡啶的化合物，然后将过量的该取代吡啶与一定量的氨基钠混合，使得混合物在足够高的温度下形成取代的2,2'-联吡啶，并分离所形成的取代2,2'-联吡啶。新的取代2,2'-联吡啶化合物包括以下化合物：4,4'-二-(5-壬基)-2,2'-联吡啶；4,4'-二-(3-戊基)-2,2'-联吡啶；6,6'-二-(3-戊基)-2,2'-联吡啶；6,6'-二-(5-壬基)-2,2'-联吡啶；4,4'-二-(环己甲基)-2,2'-联吡啶；5,5'-二-(5-壬基)-2,2'-联吡啶；4,4'-二-(3-苯基丙基)-2,2'-联吡啶；4,4'-二-(4-四氢吡喃基)-2,2'-联吡啶；4,4'-二-苄基-2,2'-联吡啶；6,6'-二-异戊基-2,2'-联吡啶；以及4,4'-二-(叔丁基)-2,2'-联吡啶。

  公开号：

  US04177349A1

文献信息

• [EN] METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACÉTYL)AMINO)-5-(DIMÉTHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE TERT-BUTYLE
  申请人：MOEHS IBERICA SL

  公开号：WO2019158550A1

  公开（公告）日：2019-08-22

  The present invention relates to a method for preparing tert-butyl N- ((1R,2S,5S)-2-((2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)amino) -5-(dimethylcarbamoyl)cyclohexyl)carbamate of formula (I), or a salt or solvate thereof,characterized in that it comprises the steps of a) mixing tert-butyl N-((1R,2S,5S)-2-amino-5-(dimethylcarbamoyl) cyclohexyl)carbamate of formula (A) with ethyl 2-((5-chloropyridin-2- yl)amino)-2-oxoacetate of formula (B) in an organic solvent; b) mixing a base with the resulting mixture of step (a); and c) stirring the mixture obtained in step (b). The method substantially facilitates the obtention of the compound of formula (I), leading to a reduction in the viscosity of the reaction medium and improving product yield and/or product purity. Formulae (I), (B), (A).

  本发明涉及一种制备式（I）的叔丁基N-((1R,2S,5S)-2-((2-((5-氯吡啶-2-基)氨基)-2-氧代乙酰)氨基)-5-(二甲基氨基)环己基)氨基甲酸酯或其盐或溶剂的方法，其特征在于包括以下步骤：a）将式（A）的叔丁基N-((1R,2S,5S)-2-氨基-5-(二甲基氨基)环己基)氨基甲酸酯与式（B）的乙酸乙酯-2-((5-氯吡啶-2-基)氨基)-2-氧代乙酸酯在有机溶剂中混合；b）将碱与步骤（a）中得到的混合物混合；c）搅拌步骤（b）中得到的混合物。该方法极大地促进了式（I）化合物的得到，降低了反应介质的粘度，提高了产物的产量和/或产物纯度。式（I），（B），（A）。
• Diazepane derivatives and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10308653B2

  公开（公告）日：2019-06-04

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

  本公开提供了式（I）化合物及其药用组合物。已发现式（I）化合物可结合溴基链和/或含溴基链的蛋白质（如溴外末端（BET）蛋白质）。还提供了这些化合物和药物组合物的方法、用途和试剂盒，用于抑制溴基团和/或含溴基团蛋白的活性（如活性增加），治疗和/或预防受试者与溴基团或含溴基团蛋白相关的疾病（如增殖性疾病、心血管疾病、病毒感染、纤维化疾病、神经系统疾病、代谢性疾病、内分泌疾病和辐射中毒）。这些化合物、药物组合物和试剂盒还可用于男性避孕。
• CYANOPHOSPHORUS COMPOUNDS AND THEIR PREPARATION
  申请人：MONSANTO COMPANY

  公开号：EP0948502A1

  公开（公告）日：1999-10-13
• EP3752488A1
  申请人：——

  公开号：EP3752488A1

  公开（公告）日：2020-12-23
• DIAZEPANE DERIVATIVES AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170145023A1

  公开（公告）日：2017-05-25

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

表征谱图